Use of a nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension

Full Text

Abstract

Idiopathic (primary) pulmonary hypertension (IPH) is a rare disease of unknown etiology, which is characterized by elevated pulmonary artery pressure, increased total pulmonary vascular resistance, frequently a malignant course with evolving right ventricular decompensation, and a fatal outcome. The diagnosis of IPH is established on the increments in the mean resting and exercise pulmonary artery trunk pressure by more than 25 and more than 30 mm Hg at rest and during exercise, respectively, with a normal pulmonary artery wedge pressure.
Endothelin receptor antagonists (ERA) are one of the effective classes of drugs for the treatment of patients with IPH. Bosentan is the first drug from the ERA class that blocks the receptors of both types and that has been recommended by the WHO to treat patients with functional class II-IV pulmonary hypertension.
The described case demonstrates the possibility of concomitantly using bosentan in a female patient with IPH shortly after ineffective treatment with a calcium antagonist.

About the authors

Ol'ga Aleksandrovna Arkhipova

Tamila Vital'evna Martynyuk

Valentina Kirillovna Lazutkina

Dil'bar Mukumovna Ataullakhanova

Ol'ga Vladimirovna Stukalova

Nikolay Mikhaylovich Danilov

Lyudmila Evgen'evna Samoylenko

Irina Evgen'evna Chazova

O A Arkhipova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

T V Martynyuk

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

V K Lazutkina

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

D M Ataullakhanova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

O V Stukalova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

N M Danilov

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

L E Samoilenko

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

I E Chazova

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies

References

  1. Беленков Ю. Н., Чазова И. Е. Первичная легочная гипертензия. М.: Нолидж; 1999.
  2. D'Alonzo G. E., Barst R. J., Ayres S. M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343-349.
  3. Диагностика и лечение легочной гипертензии: Российские рекомендации ВНОК. М.; 2007.
  4. Мартынюк Т. В., Масенко В. П., Чазова И. Е. и др. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология 1997; 10: 25-29.
  5. Lopes A. A., Maeda N. Y., Gongalves R. C., Bydlowski S. P. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am. Heart J. 2000; 139 (4): 618-623.
  6. Guidelines for the diagnosis and treatment of pulmonary hypertension. Update 2009. European society of cardiology. Eur. Heart J. 2009; 30: 2493-2537.
  7. Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346 (12): 896-903.
  8. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004; 351: 1425-1436.
  9. Clozel M. Endothelin receptor antagonists: current status and perspectives. J. Cardiovasc. Pharmacol. 2000; 35: S65.
  10. Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with primary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-1123.

Statistics

Views

Abstract: 134

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 Arkhipova O.A., Martynyuk T.V., Lazutkina V.K., Ataullakhanova D.M., Stukalova O.V., Danilov N.M., Samoylenko L.E., Chazova I.E., Arkhipova O.A., Martynyuk T.V., Lazutkina V.K., Ataullakhanova D.M., Stukalova O.V., Danilov N.M., Samoilenko L.E., Chazova I.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies